Nomenclature
Short Name:
PSKH2
    Full Name:
Serine/threonine-protein kinase H2
    Alias:
- PSK-H2
Classification
Type:
Protein-serine/threonine kinase
    Group:
CAMK
    Family:
PSK
    SubFamily:
NA
    Structure
Mol. Mass (Da):
43,027
    # Amino Acids:
385
    # mRNA Isoforms:
1
    mRNA Isoforms:
43,027 Da (385 AA; Q96QS6)
    4D Structure:
NA
    1D Structure:
Subfamily Alignment

Domain Distribution:
| Start | End | Domain | 
|---|---|---|
| 63 | 320 | Pkinase | 
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
       Myristoylated:
 G2 (predicted).
 
       Serine phosphorylated:
S356, S359, S362.
Threonine phosphorylated:
T84, T85.
Tyrosine phosphorylated:
Y63.
Distribution
Based on gene microarray analysis from the NCBI
   Human Tissue Distribution
% Max Expression:  
Mean Expression:  
Number of Samples:  
Standard Deviation:  
            % Max Expression:  
Mean Expression:  
Number of Samples:  
Standard Deviation:  
    15 15
 1299
 9
 1513
 
 0.04 0.04
 3
 4
 1
 
 0.02 0.02
 2
 2
 2
 
 0.4 0.4
 35
 28
 20
 
 4 4
 311
 10
 214
 
 0.02 0.02
 2
 9
 2
 
 0.08 0.08
 7
 13
 6
 
 0.05 0.05
 4
 4
 1
 
 0.02 0.02
 2
 3
 1
 
 0.04 0.04
 3
 4
 1
 
 0.1 0.1
 12
 4
 13
 
 8 8
 655
 11
 624
 
 0.05 0.05
 4
 1
 0
 
 0.02 0.02
 2
 3
 1
 
 0.07 0.07
 6
 3
 3
 
 0.3 0.3
 26
 5
 5
 
 0.07 0.07
 6
 8
 5
 
 0.06 0.06
 5
 5
 5
 
 0.05 0.05
 4
 5
 2
 
 4 4
 375
 26
 183
 
 0.05 0.05
 4
 5
 3
 
 0.05 0.05
 4
 4
 2
 
 0.2 0.2
 19
 1
 0
 
 0.02 0.02
 2
 5
 1
 
 0.05 0.05
 4
 5
 3
 
 7 7
 547
 20
 580
 
 0.06 0.06
 5
 4
 5
 
 0.05 0.05
 4
 5
 5
 
 0.06 0.06
 5
 4
 5
 
 - -
 -
 -
 -
 
 6 6
 496
 12
 30
 
 100 100
 8394
 11
 8677
 
 0.02 0.02
 2
 12
 0
 
 8 8
 700
 26
 600
 
 2 2
 127
 22
 120
 
Evolution
Species Conservation
PhosphoNET % Identity:  
PhosphoNET % Similarity:  
  Homologene %
Identity:  
            PhosphoNET % Identity:  
PhosphoNET % Similarity:  
  Homologene %
Identity:  
    100 100
 100
 100
 97.4 97.4
 98.6
 97
 95 95
 97.1
 96
 - -
 -
 -
 - -
 -
 -
 82.8 82.8
 89.8
 82.5
 - -
 -
 -
 58.9 58.9
 73.1
 -
 38.1 38.1
 55.5
 -
 - -
 -
 -
 62 62
 74.2
 -
 60.9 60.9
 74
 -
 35 35
 54.8
 68
 58.5 58.5
 73.4
 -
 - -
 -
 -
 - -
 -
 -
 38.9 38.9
 59.7
 -
 37.3 37.3
 59.5
 -
 39.4 39.4
 52.5
 -
 - -
 -
 -
 - -
 -
 -
 - -
 -
 -
 27.4 27.4
 39.7
 35
 - -
 -
 -
 - -
 -
 -
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
    Regulation
Activation:
NA
    Inhibition:
NA
    Synthesis:
NA
    Degradation:
NA
    
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
      
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
            Domain #:
1
    Disease Linkage
Gene Expression in Cancers:
The COSMIC website notes an up-regulated expression score for PSKH2 in diverse human cancers of 295, which is 0.6-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 0 for this protein kinase in human cancers was 100% lower than the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.13 % in 24777 diverse cancer specimens. This rate is 1.8-fold higher than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.81 % in 864 skin cancers tested; 0.47 % in 1270 large intestine cancers tested; 0.45 % in 1685 lung cancers tested; 0.35 % in 589 stomach cancers tested; 0.2 % in 1276 kidney cancers tested; 0.17 % in 603 endometrium cancers tested; 0.14 % in 548 urinary tract cancers tested; 0.11 % in 238 bone cancers tested; 0.1 % in 273 cervix cancers tested; 0.07 % in 710 oesophagus cancers tested; 0.07 % in 1512 liver cancers tested; 0.06 % in 942 upper aerodigestive tract cancers tested; 0.06 % in 1316 breast cancers tested; 0.05 % in 558 thyroid cancers tested; 0.04 % in 1459 pancreas cancers tested; 0.03 % in 881 prostate cancers tested; 0.03 % in 833 ovary cancers tested; 0.01 % in 2082 central nervous system cancers tested; 0.01 % in 2009 haematopoietic and lymphoid cancers tested.
Frequency of Mutated Sites:
Most frequent mutations with the number of reports indicated in brackets: G312D (9).
Comments:
No deletions, insertions or complex mutations are noted on the COSMIC website.
 

